Abstract
Osteoporosis is a common complication observed in rheumatoid arthritis (RA). Accelerated bone loss is always a matter of concern. The pathogenesis of RA may be important for better understanding of the bone loss. The mechanism involved in the bone loss in RA is not well understood although cytokines such as interleukin 1 and tumour necrosis factor α (TNF α) have been strongly implicated. TNF α antagonists have revolutionised the treatment of RA in the recent years. Beyond the control of disease activity in RA, accumulating evidence suggests that this form of therapy may provide beneficial effects to the bone metabolism and remodeling. An extensive search of the literature was performed in the Medline, Scopus and EBSCO databases to evaluate the documented research on the effects of TNF α antagonists in RA on bone mineral density and bone turnover markers. The available data based on our systematic review, depict a significant association between TNF α antagonists treatment and suppression of bone resorption.
Keywords: Bone mineral density, osteoporosis, rheumatoid arthritis, TNF α antagonists.
Current Drug Targets
Title:The Effects of TNF α Antagonist Therapy on Bone Metabolism in Rheumatoid Arthritis: A Systematic Review
Volume: 14 Issue: 13
Author(s): Rajalingham Sakthiswary and Srijit Das
Affiliation:
Keywords: Bone mineral density, osteoporosis, rheumatoid arthritis, TNF α antagonists.
Abstract: Osteoporosis is a common complication observed in rheumatoid arthritis (RA). Accelerated bone loss is always a matter of concern. The pathogenesis of RA may be important for better understanding of the bone loss. The mechanism involved in the bone loss in RA is not well understood although cytokines such as interleukin 1 and tumour necrosis factor α (TNF α) have been strongly implicated. TNF α antagonists have revolutionised the treatment of RA in the recent years. Beyond the control of disease activity in RA, accumulating evidence suggests that this form of therapy may provide beneficial effects to the bone metabolism and remodeling. An extensive search of the literature was performed in the Medline, Scopus and EBSCO databases to evaluate the documented research on the effects of TNF α antagonists in RA on bone mineral density and bone turnover markers. The available data based on our systematic review, depict a significant association between TNF α antagonists treatment and suppression of bone resorption.
Export Options
About this article
Cite this article as:
Sakthiswary Rajalingham and Das Srijit, The Effects of TNF α Antagonist Therapy on Bone Metabolism in Rheumatoid Arthritis: A Systematic Review, Current Drug Targets 2013; 14 (13) . https://dx.doi.org/10.2174/13894501113149990176
DOI https://dx.doi.org/10.2174/13894501113149990176 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Progress of Small Molecular VEGFR Inhibitors as Anticancer Agents
Mini-Reviews in Medicinal Chemistry Selectivity, Binding Affinity, and Ionization State of Matrix Metalloproteinase Inhibitors
Current Pharmaceutical Design Venous Thromboembolism Risk and Adequacy of Prophylaxis in High Risk Pregnancy in the Arabian Gulf
Current Vascular Pharmacology Oxidized LDL Antibodies in Treatment and Risk Assessment of Atherosclerosis and Associated Cardiovascular Disease
Current Pharmaceutical Design Immunobiology of Herpes Simplex Virus and Cytomegalovirus Infections of the Fetus and Newborn
Current Immunology Reviews (Discontinued) Hemoglobin Degrading Proteases of Plasmodium falciparum as Antimalarial Drug Targets
Current Drug Targets Hymenoptera Venom Proteins and Peptides for Diagnosis and Treatment of Venom Allergic Patients
Inflammation & Allergy - Drug Targets (Discontinued) n-Butyl-α-D-fructofuranoside Isolated from Ulmus davidiana Enhances Nrf2 Activity Through Activation of JNK
Current Pharmaceutical Biotechnology Preface
Current Pharmaceutical Design Wound Healing and Antimicrobial Potential of Oroxylum indicum Vent. in Albino Mice
The Natural Products Journal The Involvement of the Nitric Oxide in the Effects and Expression of Opioid Receptors During Peripheral Inflammation
Current Medicinal Chemistry Target Sites for the Design of Anti-trypanosomatid Drugs Based on the Structure of Dihydroorotate Dehydrogenase
Current Pharmaceutical Design Recent Advances in Neuro-Endocrine-Immune Interactions in the Pathophysiology of Rheumatoid Arthritis
Current Rheumatology Reviews Editorial [Innovative Therapeutic Approaches for the Treatment of Pediatric Autoimmune and Inflammatory Diseases Executive (Guest Editor: Giorgio Zauli)]
Current Pharmaceutical Design Subject Index To Volume 7
Current Pharmaceutical Biotechnology Systemic Sclerosis-Related Pulmonary Hypertension: Unique Characteristics and Future Treatment Targets
Current Pharmaceutical Design Anti-Inflammatory Activities of Some Bee Products by Inhibition of Bovine Testes Hyaluronidase
Current Enzyme Inhibition Clinical Review of COVID-19; Pathogenesis, Diagnosis, and Management
Current Pharmaceutical Design Immunosuppressive Treatments in Acute Myocardial Infarction and Stroke
Current Pharmaceutical Biotechnology Methotrexate Hepatotoxicity in Rheumatoid Arthritis: An Analysis of the Physicians’ Policy
Current Rheumatology Reviews